Glipizide Tablet, Extended Release shortage
To Be DiscontinuedGlipizide Tablet, Extended Release is currently listed as To Be Discontinued in the FDA Drug Shortage Database. Reported reason: Not specified.
Therapeutic category
Dosage form
Tablet
Routes
ORAL
Last updated
07/24/2025
Strength variants
- Not specified
Need sourcing help for Glipizide Tablet, Extended Release?
Get connected with licensed distributors and 503B compounders that can fulfill orders during active shortages. Verified suppliers, no spam.
Connect with a sourcing partnerManufacturers reporting shortage
- Pfizer Inc.800-533-4535To Be Discontinued
Reason for shortage
ad slot 300x250
Related shortages in Endocrinology/Metabolism
Dextrose Monohydrate 10% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
Dextrose Monohydrate 5% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
Dextrose Monohydrate 5% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
Dextrose Monohydrate 5% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
Dextrose Monohydrate 5% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
Dextrose Monohydrate 10% Injection
- Category
- Endocrinology/Metabolism
- Reason
- Not specified
- Updated
- 04/07/2026
This information is not medical advice. Consult your pharmacist. Data is sourced from the FDA Drug Shortage Database and may not reflect real-time inventory at your facility. ShortageWatch is independent and not affiliated with the FDA.